Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia
- 27 July 2022
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 63 (12) , 2948-2954
Abstract
A total of 548 patients (age range: 1–22 years, 60.4% Hispanic, 55.8% male) diagnosed with acute lymphoblastic leukemia were reviewed for pegaspargase-associated hypersensitivity (14.8%), hyperbilirubinemia (9.7%), venous thromboembolism (VTE, 9.7%), and pancreatitis (5.3%). Odds ratios (OR) and 95% confidence intervals (CI) evaluated associations between clinical factors and each toxicity, cumulative number of toxicities, and toxicity clusters identified using k-mode analysis. Most (68.9%) did not experience any toxicity, 24.6% experienced one toxicity, and 6.3% two or more. Age >10 years was associated with hyperbilirubinemia (OR = 3.83; 95% CI: 1.64–8.95), pancreatitis (OR = 3.72; 95% CI: 1.29–10.68), VTE (OR = 4.65; 95% CI: 1.96–11.02), and cumulative toxicity burden (OR = 3.28, 95% CI: 1.97–5.47); high-risk therapy with hypersensitivity (OR 2.25; 95% CI 1.25–4.05); and overweight with cumulative toxicity burden (OR = 1.76, 95% CI: 1.20–2.57). Eight unique toxicity profiles were identified. Older age, overweight, and treatment intensity contribute to pegaspargase-associated toxicities.Keywords
Funding Information
- National Institutes of Health National Cancer Institute (P20CA262733, K07CA218362)
- The Cancer Prevention Research Institute of Texas (RP160771, RP170668)
- The St. Baldrick’s Foundation Consortium Research (522277)
- Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium
- Cancer Prevention and Research Institute of Texas and St. Baldrick's Foundation
This publication has 37 references indexed in Scilit:
- Increased Pancreatic Fat Fraction Is Present in Obese Adolescents With Metabolic SyndromeJournal of Pediatric Gastroenterology and Nutrition, 2012
- Delivery of Therapeutic ProteinsJournal of Pharmaceutical Sciences, 2010
- Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group StudyJournal of Clinical Oncology, 2009
- Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemiaPediatric Blood & Cancer, 2009
- Obesity-Associated Liver DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2008
- Body Mass Index Measurement in Schools*Journal of School Health, 2007
- FDA Drug Approval Summary: Pegaspargase (Oncaspar®) for the First-Line Treatment of Children with Acute Lymphoblastic Leukemia (ALL)The Oncologist, 2007
- A Note on K-modes ClusteringJournal of Classification, 2003
- A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group studyBlood, 2002
- Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01Blood, 2001